E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ewing family of tumours Osteosarcoma Hodgkin lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
Ewing family of tumours is a cancer that affects bones and soft tissues, osteosarcoma is a primary bone cancer, and Hodkin lyphoma is a cancer of the lymph glands. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020328 |
E.1.2 | Term | Hodgkin's lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10015570 |
E.1.2 | Term | Ewing's tumour |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10031291 |
E.1.2 | Term | Osteosarcoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of gender on the pharmacokinetics (PK) of doxorubicin in AYA* patients with newly diagnosed: -Ewing family of tumours (EFT)** -Osteosarcoma (OS); or -Hodgkin lymphoma (HL) *AYA is defined as young people who have entered puberty (Tanner stage ≥2) or are pubertally mature, regardless of whether they are being treated on an adult chemotherapy regimen or a children’s chemotherapy regimen. **EFT includes Ewing’s sarcoma of bone, extra-osseous Ewing Sarcoma, and PNET (primitive neuroectodermal tumour) outside the central nervous system. |
|
E.2.2 | Secondary objectives of the trial |
1) To evaluate the effect of gender and pubertal stage on the pharmacokinetics(PK) of doxorubicin in children and AYA with newly diagnosed: - Ewing family of tumours (EFT); or - Osteosarcoma (OS)
2)To explore the relationship between doxorubicin PK and doxorubicin pharmacodynamics (PD), in children and AYA with newly diagnosed EFT, OS or HL, where PD is measured by each of the following metrics in turn:
a)Worst grade of neutropenia( Low white blood Cells), thrombocytopenia (Low Platelets), or mucositis (Sore Mouth) in cycle 1 of chemotherapy, as measured at the scheduled assessment times .
b) Tumour response, which will be measured in different ways for different groups of patients as follows - by International Working Group Criteria 33 for HL patients;
- by tumour necrosis( Amount of dead tumour following chemotherapy) for OS and EFT patients where surgery is performed; and
- by RECIST criteria (RECIST creiteria is an objective scheme for measuring tumour resp |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Newly diagnosed with osteosarcoma, Ewing family of tumours or Hodgkin lymphoma - ≥1 year and 40years of age (in the UK only patients aged 11 - 40 years will be recruited) - Planned treatment involves standard of care doxorubicin-containing regimens. - Written informed consent from patient and/or patient’s parent or legal guardian.
|
|
E.4 | Principal exclusion criteria |
- Impaired hepatic function such as known chronic liver disease, evidence of impaired synthetic function or transaminases raised >5 x normal
- Significant uncontrolled systemic illness as judged by investigator
- Females who are pregnant or breast feeding
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be AUC (Area Under the Curve) calculated from the doxorubicin concentration-time curves (Ct) derived from the PK samples.
N.B The primary aim of the study is to evaluate the effect of gender on pharmacokinetcs of doxorubicin in children and young adults with newly diagnosed Ewing family of tumours, osteosarcoma and Hodgkin lymphoma.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The PK will be evaluated during the first cycle of chemotherapy. |
|
E.5.2 | Secondary end point(s) |
To evaluate the effect of gender and pubertal stage on the pharmacokinetics (PK) of doxorubicin in children and adolescents and young adults (AYA) with newly diagnosed Ewing family of tumours (EFT) or osteosarcoma (OS). To explore the relationship between doxorubicin PK and pharmacodynamics (PD)in children and AYA wtih newly diagnosed EFT, OS and Hodgkin lymphoma, where PD is measured by: - worst grade of neutropenia, thrombocytopenia, or mucositis in cycle 1 of chemotherapy - tumour response (on imaging, and resection specimen of EFT and OS patients undergoing surgery). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The worst grade of neutropenia, thrombocytopenia, or mucositis will be evaluated at the end of cycle 1 of chemotherapy. Tumour response will be evaluated by imaging at the first imaging time point as specified by the standard treatment schedule for the different tumours; and by surgery which is carried out after the initial block of chemotherapy for EFT and OS as specified buy the standard treatment schedule. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description |
This is an observational PK study of an established agent, doxorubicin. |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as after the last patient has had surgery, or in the absence of surgery, after imaging (CT or MRI scan) has been been performed to assess response to chemotherapy. This will be after the last clinic visit of patients. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |